{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:31:09Z","timestamp":1787020269765,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti-contactin-1 antibody-associated autoimmune nodopathy (CNTN1-AN) is a rare disorder predominantly affecting older individuals, characterized by sensorimotor peripheral neuropathy, with over 50% of cases presenting with proteinuria and membranous nephropathy (MN). Pediatric-onset CNTN1-AN is exceptionally rare, and its clinical profile remains poorly characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation and literature review<\/jats:title>\n                    <jats:p>We report a pediatric case of CNTN1-AN with MN and conduct a literature review to elucidate the pathogenesis and clinical features of CNTN1-AN combined with MN in children. The patient, an 11-year-old girl, presented with a one-month history of progressive lower limb weakness and a 10-day progression of gait instability. Physical examination demonstrated bilateral proximal lower limb weakness, restricted mobility, and sensory abnormalities.No facial or limb edema or frothy urine was observed. Elevated anti-CNTN1 antibody titers were detected in both serum (1:320) and cerebrospinal fluid (CSF) (1:3.2). Urinalysis showed significant proteinuria (4+). Electromyography (EMG) indicated peripheral nerve involvement, and lumbosacral and brachial plexus magnetic resonance imaging (MRI) demonstrated nerve root edema and thickening. Renal biopsy confirmed stage I MN, establishing the diagnosis of CNTN1-AN with MN. Following prednisone and rituximab therapy, motor function improved, though renal progression persisted. A comprehensive literature review identified six confirmed pediatric CNTN1-AN cases globally. Including the current case, renal involvement was observed in 3\/7 pediatric cases, with MN confirmed in two. Comparative analysis indicates that CNTN1-AN manifests similarly across pediatric and adult populations, though pediatric cases demonstrate potentially lower incidence rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pediatric CNTN1-AN exhibits a low incidence, requiring ongoing renal function monitoring in affected cases. In CNTN1-AN with MN, neurological symptoms respond well to low-dose rituximab, whereas renal manifestations often require intensified regimens. The mechanisms linking CNTN1-AN and MN remain elusive, highlighting the need for further studies to optimize rituximab therapeutic protocols.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12887-025-06429-3","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T14:17:24Z","timestamp":1768573044000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characteristics of pediatric-onset anti-contactin1 antibody-associated autoimmune nodopathies with concomitant membranous nephropathy"],"prefix":"10.1186","volume":"26","author":[{"given":"Qiuyue","family":"Guan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghua","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liru","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"issue":"11","key":"6429_CR1","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1111\/ene.14959","volume":"28","author":"PYK Van den Bergh","year":"2021","unstructured":"Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European academy of Neurology\/Peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task Force-Second revision [J]. Eur J Neurol. 2021;28(11):3556\u201383. https:\/\/doi.org\/10.1111\/ene.14959.","journal-title":"Eur J Neurol"},{"issue":"6","key":"6429_CR2","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.kint.2021.08.014","volume":"100","author":"M Le Quintrec","year":"2021","unstructured":"Le Quintrec M, Teisseyre M, Bec N, et al. Contactin-1 is a novel target antigen in membranous nephropathy associated with chronic inflammatory demyelinating polyneuropathy [J]. Kidney Int. 2021;100(6):1240\u20139. https:\/\/doi.org\/10.1016\/j.kint.2021.08.014.","journal-title":"Kidney Int"},{"key":"6429_CR3","doi-asserted-by":"publisher","unstructured":"Caballero-\u00c1vila M, Mart\u00edn-Aguilar L, Pascual-Go\u00f1i E et al. Long-Term follow up in Anti-Contactin-1 autoimmune nodopathy [J]. Ann Neurol, 2024https:\/\/doi.org\/10.1002\/ana.27142","DOI":"10.1002\/ana.27142"},{"key":"6429_CR4","doi-asserted-by":"publisher","first-page":"578460","DOI":"10.1016\/j.jneuroim.2024.578460","volume":"396","author":"Y Liu","year":"2024","unstructured":"Liu Y, Yang CL, Zhao XL, et al. Characteristics of anti-contactin1 antibody positive autoimmune nodopathies combined with membranous nephropathy [J]. J Neuroimmunol. 2024;396:578460. https:\/\/doi.org\/10.1016\/j.jneuroim.2024.578460.","journal-title":"J Neuroimmunol"},{"issue":"8","key":"6429_CR5","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1159\/000528078","volume":"147","author":"LF Al-Rabadi","year":"2023","unstructured":"Al-Rabadi LF, Beck LH Jr. Neuronal proteins as antigenic targets in membranous nephropathy [J]. Nephron. 2023;147(8):451\u20137. https:\/\/doi.org\/10.1159\/000528078.","journal-title":"Nephron"},{"issue":"4s","key":"6429_CR6","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases [J]","year":"2021","unstructured":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases [J]. Kidney Int. 2021;100(4s):S1. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021.","journal-title":"Kidney Int"},{"key":"6429_CR7","doi-asserted-by":"publisher","first-page":"1368487","DOI":"10.3389\/fimmu.2024.1368487","volume":"15","author":"M Zhao","year":"2024","unstructured":"Zhao M, Chen G, Li S, et al. Recurrent CNTN1 antibody-positive nodopathy: a case report and literature review [J]. Front Immunol. 2024;15:1368487. https:\/\/doi.org\/10.3389\/fimmu.2024.1368487.","journal-title":"Front Immunol"},{"key":"6429_CR8","doi-asserted-by":"publisher","first-page":"759187","DOI":"10.3389\/fimmu.2021.759187","volume":"12","author":"Q Xu","year":"2021","unstructured":"Xu Q, Liu S, Zhang P, et al. Characteristics of Anti-Contactin1 Antibody-Associated autoimmune nodopathies with concomitant membranous nephropathy [J]. Front Immunol. 2021;12:759187. https:\/\/doi.org\/10.3389\/fimmu.2021.759187.","journal-title":"Front Immunol"},{"key":"6429_CR9","doi-asserted-by":"publisher","unstructured":"Cortese A, Lombardi R, Briani C, et al. Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: clinical relevance of IgG isotype [J]. Neurol Neuroimmunol Neuroinflamm. 2020;7(1). https:\/\/doi.org\/10.1212\/nxi.0000000000000639.","DOI":"10.1212\/nxi.0000000000000639"},{"key":"6429_CR10","doi-asserted-by":"publisher","unstructured":"Carrera-Garc\u00eda L, Natera-de Benito D, Lleix\u00e0 C, et al. Chronic inflammatory demyelinating polyneuropathy associated with contactin-1 antibodies in a child [J]. Neurol Neuroimmunol Neuroinflamm. 2019;6(5). https:\/\/doi.org\/10.1212\/nxi.0000000000000602.","DOI":"10.1212\/nxi.0000000000000602"},{"key":"6429_CR11","doi-asserted-by":"publisher","unstructured":"De Simoni D, Ricken G, Winklehner M, et al. Antibodies to nodal\/paranodal proteins in paediatric immune-mediated neuropathy [J]. Neurol Neuroimmunol Neuroinflamm. 2020;7(4). https:\/\/doi.org\/10.1212\/nxi.0000000000000763.","DOI":"10.1212\/nxi.0000000000000763"},{"issue":"1","key":"6429_CR12","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1136\/jnnp-2023-331378","volume":"95","author":"MC Broers","year":"2023","unstructured":"Broers MC, Wieske L, Erdag E, et al. Clinical relevance of distinguishing autoimmune nodopathies from CIDP: longitudinal assessment in a large cohort [J]. J Neurol Neurosurg Psychiatry. 2023;95(1):52\u201360. https:\/\/doi.org\/10.1136\/jnnp-2023-331378.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6429_CR13","doi-asserted-by":"publisher","first-page":"1308068","DOI":"10.3389\/fimmu.2024.1308068","volume":"15","author":"J Chen","year":"2024","unstructured":"Chen J, Liu L, Zhu H, et al. Autoimmune nodopathy with anti-contactin 1 antibody characterized by cerebellar dysarthria: a case report and literature review [J]. Front Immunol. 2024;15:1308068. https:\/\/doi.org\/10.3389\/fimmu.2024.1308068.","journal-title":"Front Immunol"},{"issue":"5","key":"6429_CR14","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/acn3.51754","volume":"10","author":"Y Tang","year":"2023","unstructured":"Tang Y, Liu J, Gao F, et al. CIDP\/autoimmune nodopathies with nephropathy: a case series study [J]. Ann Clin Transl Neurol. 2023;10(5):706\u201318. https:\/\/doi.org\/10.1002\/acn3.51754.","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"6429_CR15","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1093\/brain\/awab014","volume":"144","author":"E Pascual-Go\u00f1i","year":"2021","unstructured":"Pascual-Go\u00f1i E, Fehmi J, Lleix\u00e0 C, et al. Antibodies to the Caspr1\/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy [J]. Brain. 2021;144(4):1183\u201396. https:\/\/doi.org\/10.1093\/brain\/awab014.","journal-title":"Brain"},{"key":"6429_CR16","doi-asserted-by":"publisher","first-page":"107521","DOI":"10.1016\/j.clineuro.2022.107521","volume":"223","author":"M Dong","year":"2022","unstructured":"Dong M, Tai H, Yang S, et al. Characterization of the patients with antibodies against nodal-paranodal junction proteins in chronic inflammatory demyelinating polyneuropathy [J]. Clin Neurol Neurosurg. 2022;223:107521. https:\/\/doi.org\/10.1016\/j.clineuro.2022.107521.","journal-title":"Clin Neurol Neurosurg"},{"key":"6429_CR17","doi-asserted-by":"publisher","first-page":"1124540","DOI":"10.3389\/fneur.2023.1124540","volume":"14","author":"Q Li","year":"2023","unstructured":"Li Q, Chen Q, Zhang T, et al. Case report: Anti-CNTN1 antibody-associated nodopathies disease with asymmetric onset [J]. Front Neurol. 2023;14:1124540. https:\/\/doi.org\/10.3389\/fneur.2023.1124540.","journal-title":"Front Neurol"},{"issue":"1","key":"6429_CR18","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00415-022-11369-4","volume":"270","author":"S Zhang","year":"2023","unstructured":"Zhang S, Yang S, Lu J, et al. CIDP-like autoimmune nodopathy complicated with focal segmental glomerulosclerosis: a case study and literature review [J]. J Neurol. 2023;270(1):493\u2013502. https:\/\/doi.org\/10.1007\/s00415-022-11369-4.","journal-title":"J Neurol"},{"key":"6429_CR19","doi-asserted-by":"publisher","unstructured":"Hashimoto Y, Ogata H, Yamasaki R, et al. Chronic Inflammatory Demyelinating Polyneuropathy With Concurrent Membranous Nephropathy: An Anti-paranode and Podocyte Protein Antibody Study and Literature Survey [J]. Front Neurol. 2018;9:997. https:\/\/doi.org\/10.3389\/fneur.2018.00997.","DOI":"10.3389\/fneur.2018.00997"},{"issue":"10","key":"6429_CR20","doi-asserted-by":"publisher","first-page":"e16406","DOI":"10.1111\/ene.16406","volume":"31","author":"K Funakoshi","year":"2024","unstructured":"Funakoshi K, Kokubun N, Suzuki K, et al. Proteinuria is a key to suspect autoimmune nodopathies [J]. Eur J Neurol. 2024;31(10):e16406. https:\/\/doi.org\/10.1111\/ene.16406.","journal-title":"Eur J Neurol"},{"key":"6429_CR21","doi-asserted-by":"publisher","unstructured":"Gr\u00fcner J, Stengel H, Werner C, et al. Anti-contactin-1 antibodies affect surface expression and sodium currents in dorsal root ganglia [J]. Neurol Neuroimmunol Neuroinflamm. 2021;8(5). https:\/\/doi.org\/10.1212\/nxi.0000000000001056.","DOI":"10.1212\/nxi.0000000000001056"},{"issue":"6","key":"6429_CR22","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1136\/jnnp-2016-314895","volume":"88","author":"H Koike","year":"2017","unstructured":"Koike H, Kadoya M, Kaida KI, et al. Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies [J]. J Neurol Neurosurg Psychiatry. 2017;88(6):465\u201373. https:\/\/doi.org\/10.1136\/jnnp-2016-314895.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"6429_CR23","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.clinph.2020.01.013","volume":"131","author":"L Kouton","year":"2020","unstructured":"Kouton L, Boucraut J, Devaux J, et al. Electrophysiological features of chronic inflammatory demyelinating polyradiculoneuropathy associated with IgG4 antibodies targeting neurofascin 155 or contactin 1 glycoproteins [J]. Clin Neurophysiol. 2020;131(4):921\u20137. https:\/\/doi.org\/10.1016\/j.clinph.2020.01.013.","journal-title":"Clin Neurophysiol"},{"issue":"5","key":"6429_CR24","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/wco.0000000000001107","volume":"35","author":"L Mart\u00edn-Aguilar","year":"2022","unstructured":"Mart\u00edn-Aguilar L, Lleix\u00e0 C, Pascual-Go\u00f1i E. Autoimmune nodopathies, an emerging diagnostic category [J]. Curr Opin Neurol. 2022;35(5):579\u201385. https:\/\/doi.org\/10.1097\/wco.0000000000001107.","journal-title":"Curr Opin Neurol"},{"issue":"11","key":"6429_CR25","doi-asserted-by":"publisher","first-page":"7907","DOI":"10.1074\/jbc.M113.528489","volume":"289","author":"M Labasque","year":"2014","unstructured":"Labasque M, Hivert B, Nogales-Gadea G, et al. Specific contactin N-glycans are implicated in neurofascin binding and autoimmune targeting in peripheral neuropathies [J]. J Biol Chem. 2014;289(11):7907\u201318. https:\/\/doi.org\/10.1074\/jbc.M113.528489.","journal-title":"J Biol Chem"},{"key":"6429_CR26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fimmu.2013.00235","volume":"4","author":"AM Collins","year":"2013","unstructured":"Collins AM, Jackson KJ. A Temporal model of human IgE and IgG antibody function [J]. Front Immunol. 2013;4:235. https:\/\/doi.org\/10.3389\/fimmu.2013.00235.","journal-title":"Front Immunol"},{"issue":"9","key":"6429_CR27","doi-asserted-by":"publisher","first-page":"6301","DOI":"10.1007\/s00415-024-12597-6","volume":"271","author":"N Kokubun","year":"2024","unstructured":"Kokubun N, Tsuchiya T, Hamaguchi M, et al. IgG subclass shifts occurring at acute exacerbations in autoimmune nodopathies [J]. J Neurol. 2024;271(9):6301\u201312. https:\/\/doi.org\/10.1007\/s00415-024-12597-6.","journal-title":"J Neurol"},{"issue":"3","key":"6429_CR28","doi-asserted-by":"publisher","first-page":"e0281156","DOI":"10.1371\/journal.pone.0281156","volume":"18","author":"J Fehmi","year":"2023","unstructured":"Fehmi J, Davies AJ, Antonelou M, et al. Contactin-1 links autoimmune neuropathy and membranous glomerulonephritis [J]. PLoS ONE. 2023;18(3):e0281156. https:\/\/doi.org\/10.1371\/journal.pone.0281156.","journal-title":"PLoS ONE"},{"issue":"Suppl 3","key":"6429_CR29","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1111\/jns.12570","volume":"28","author":"L Querol","year":"2023","unstructured":"Querol L, Delmont E, Lleix\u00e0 C. The autoimmune vulnerability of the node of Ranvier [J]. J Peripher Nerv Syst. 2023;28(Suppl 3):S12\u201322. https:\/\/doi.org\/10.1111\/jns.12570.","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"6429_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","volume":"7","author":"P Ronco","year":"2021","unstructured":"Ronco P, Beck L, Debiec H, et al. Membranous nephropathy [J]. Nat Rev Dis Primers. 2021;7(1):69. https:\/\/doi.org\/10.1038\/s41572-021-00303-z.","journal-title":"Nat Rev Dis Primers"},{"key":"6429_CR31","doi-asserted-by":"publisher","first-page":"939062","DOI":"10.3389\/fimmu.2022.939062","volume":"13","author":"Y Hou","year":"2022","unstructured":"Hou Y, Zhang C, Yu X, et al. Effect of low-dose rituximab treatment on autoimmune nodopathy with anti-contactin 1 antibody [J]. Front Immunol. 2022;13:939062. https:\/\/doi.org\/10.3389\/fimmu.2022.939062.","journal-title":"Front Immunol"},{"issue":"10","key":"6429_CR32","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/ndt\/gfw251","volume":"32","author":"G Moroni","year":"2017","unstructured":"Moroni G, Depetri F, Del Vecchio L, et al. Low-dose rituximab is poorly effective in patients with primary membranous nephropathy [J]. Nephrol Dial Transpl. 2017;32(10):1691\u20136. https:\/\/doi.org\/10.1093\/ndt\/gfw251.","journal-title":"Nephrol Dial Transpl"},{"issue":"3","key":"6429_CR33","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/ckj\/sfx105","volume":"11","author":"S Bagchi","year":"2018","unstructured":"Bagchi S, Subbiah AK, Bhowmik D, et al. Low-dose rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience [J]. Clin Kidney J. 2018;11(3):337\u201341. https:\/\/doi.org\/10.1093\/ckj\/sfx105.","journal-title":"Clin Kidney J"},{"issue":"5","key":"6429_CR34","doi-asserted-by":"publisher","first-page":"699","DOI":"10.2169\/internalmedicine.2126-23","volume":"63","author":"R Shida","year":"2024","unstructured":"Shida R, Iwakura T, Ohashi N, et al. Anti-contactin 1 Antibody-associated membranous nephropathy in chronic inflammatory demyelinating polyneuropathy with several autoantibodies [J]. Intern Med. 2024;63(5):699\u2013705. https:\/\/doi.org\/10.2169\/internalmedicine.2126-23.","journal-title":"Intern Med"},{"issue":"2","key":"6429_CR35","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.kint.2021.03.028","volume":"100","author":"GB Lerner","year":"2021","unstructured":"Lerner GB, Virmani S, Henderson JM, et al. A conceptual framework linking immunology, pathology, and clinical features in primary membranous nephropathy [J]. Kidney Int. 2021;100(2):289\u2013300. https:\/\/doi.org\/10.1016\/j.kint.2021.03.028.","journal-title":"Kidney Int"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-025-06429-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-025-06429-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-025-06429-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:45:05Z","timestamp":1781631905000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12887-025-06429-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6429"],"URL":"https:\/\/doi.org\/10.1186\/s12887-025-06429-3","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"8 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology under approval number TJ-IRB20250637. Written informed consent was obtained from the participant\u2019s parent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The parents of this patient have provided a written informed consent to publication of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"163"}}